sorafenib has been researched along with Endometriosis in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kadastik, Ü; Lavogina, D; Lavrits, A; Meltsov, A; Peters, M; Rinken, A; Salumets, A; Samuel, K; Sõritsa, D | 1 |
| Benedetto, C; Bussolati, B; Moggio, A; Pittatore, G; Revelli, A | 1 |
| Akkar, OB; Cetin, A; Kacan, SB; Kacan, T; Karakus, S; Ozer, H; Yildiz, C | 1 |
| Batteux, F; Cerles, O; Chapron, C; Chouzenoux, S; Dousset, B; Leconte, M; Marcellin, L; Santulli, P | 1 |
| Açmaz, G; Akkar, OB; Atilgan, R; Boztosun, A; Kosar, MI; Ozer, H | 1 |
| Bussolati, B; Cassoni, P; Marchino, GL; Moggio, A; Pittatore, G; Revelli, A | 1 |
1 review(s) available for sorafenib and Endometriosis
| Article | Year |
|---|---|
Endometrial adult/progenitor stem cells: pathogenetic theory and new antiangiogenic approach for endometriosis therapy.
Topics: Adult; Adult Stem Cells; Angiogenesis Inhibitors; Animals; Endometriosis; Endometrium; Female; Humans; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Sorafenib | 2014 |
5 other study(ies) available for sorafenib and Endometriosis
| Article | Year |
|---|---|
Chemosensitivity and chemoresistance in endometriosis - differences for ectopic versus eutopic cells.
Topics: Adult; Aminobenzoates; Apoptosis; Caspase 3; Cell Survival; Cells, Cultured; Doxorubicin; Drug Resistance; Endometriosis; Endometrium; Epithelial Cells; Female; Humans; Necrosis; Oligopeptides; Oxadiazoles; Peritoneal Diseases; Sorafenib; Stromal Cells; Young Adult | 2019 |
Effects of Pazopanib, Sunitinib, and Sorafenib, Anti-VEGF Agents, on the Growth of Experimental Endometriosis in Rats.
Topics: Angiogenesis Inhibitors; Animals; Apoptosis; bcl-2-Associated X Protein; Cell Proliferation; Disease Models, Animal; Endometriosis; Endometrium; Female; Indazoles; Indoles; Niacinamide; Ovarian Reserve; Phenylurea Compounds; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Rats, Wistar; Signal Transduction; Sorafenib; Sulfonamides; Sunitinib; Vascular Endothelial Growth Factor A | 2015 |
Inhibition of MAPK and VEGFR by Sorafenib Controls the Progression of Endometriosis.
Topics: Adult; Animals; Apoptosis; Case-Control Studies; Cell Proliferation; Cells, Cultured; Disease Models, Animal; Disease Progression; Dose-Response Relationship, Drug; Endometriosis; Endometrium; Extracellular Signal-Regulated MAP Kinases; Female; Heterografts; Humans; Mice, Nude; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Signal Transduction; Sorafenib; Stromal Cells; Time Factors; Vascular Endothelial Growth Factor Receptor-2 | 2015 |
The efficacy of bevacizumab, sorafenib, and retinoic acid on rat endometriosis model.
Topics: Administration, Oral; Animals; Antibodies, Monoclonal, Humanized; Bevacizumab; Disease Models, Animal; Endometriosis; Female; Microvessels; Niacinamide; Phenylurea Compounds; Random Allocation; Rats; Rats, Wistar; Sorafenib; Treatment Outcome; Tretinoin | 2013 |
Sorafenib inhibits growth, migration, and angiogenic potential of ectopic endometrial mesenchymal stem cells derived from patients with endometriosis.
Topics: Adult; Angiogenesis Inhibitors; Benzenesulfonates; Cell Movement; Cell Proliferation; Cells, Cultured; Endometriosis; Endometrium; Female; Humans; Mesenchymal Stem Cells; Middle Aged; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Treatment Outcome; Young Adult | 2012 |